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Abstract
Background: one of the World Health Organization Millennium Development Goal is to reduce tuberculosis
incidence by 2015. However, more of 8.5 million tuberculosis cases have been reported in 2011, with an increase
of multidrug-resistant strains. Therefore, the World Health Organization target cannot be reach without the help of
a vaccine able to limit the spread of tuberculosis. Nowadays, bacille Calmette-Guérin is the only vaccine available
against tuberculosis. It prevents against meningeal and disseminated tuberculosis in children, but its effectiveness
against pulmonary form in adolescents and adults is argued.
Method: a systematic review was performed by searches of Pubmed, references of the relevant articles and Aeras
and ClinicalTrial.gov websites.
Results: 100 articles were included in this review. Three viral vectored booster vaccines, five protein adjuvant
booster vaccines, two priming vaccines and two therapeutic vaccines have been analyzed.
Conclusions: Several vaccines are in the pipeline, but further studies on basic research, clinical trial and mass
vaccination campaigns are needed to achieve the TB eradication target by 2050.
Background
One of the World Health Organization (WHO) Millen-
nium Development goals (MDGs) is to reduce tubercu-
losis (TB) incidence by 2015. The targets of the Stop
TB Partnership, an international coalition designed to
coordinate the efforts against TB, are to halve deaths
and prevalence of TB by 2015, relative to 1990 levels
and to reduce the global incidence of less than one per
million population by 2050 [1].
However, WHO reported an estimated 8.7 million new
TB cases in 2011, 0.5 million of which occurred among
children, and 1.4 million deaths [2]. Among incident cases,
13% are co-infected with human immunodeficiency virus
(HIV) [2]. An additional threat to TB control includes the
spread of multidrug-resistant (MDR) strains. Among TB-
treatment-naïve cases, 3.7% have been estimated to be
MDR, percentage that reaches 20% in previously treated
TB cases [2].
Considering the above mentioned data and that an
active TB case will typically infect 10-15 contacts,
advances in diagnostic and therapeutic strategies are not
sufficient to achieve the goal of elimination of TB by 2050
[3]. Therefore, new vaccines development is urgently
needed for the control of TB. A vaccine will limit initial
infection, progression of disease and reactivation of latent
TB [4]. Moreover, it can also be an essential tool in tack-
ling the spread of MDR TB.
Nowadays, bacille Calmette-Guérin (BCG) is still the
only vaccine available against TB. It was firstly adminis-
tered as oral vaccine to an infant in 1921 and it is still the
only vaccine licensed to prevent TB. It is a live attenuated
strain of Mycobacterium bovis, obtained by Albert Calm-
ette and Camille Guérin through 230 in vitro passages
over a 13 year-period [5]. Since daughter strains of BCG
have been distributed around the world to produce vac-
cine in manufacture, genetic and antigenic differences
have emerged between vaccine strains [6]. Thus, global
concerns about safety and efficacy between different
strains arose.
BCG is widely used in TB endemic countries, where
newborns are immunized as soon as possible after birth
with a single intradermal dose [7]. To date, it is esti-
mated that BCG has been administered over 4 billion
times and that 120 million children receive BCG every
year globally [8].
Meta-analyses of published studies have clearly reported
that BCG prevents against meningeal TB and disseminated
forms in children [9,10]. However, randomized clinical
trials have reported estimates of protection against
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pulmonary TB that vary from nil to 80% [6,11]. Therefore,
since pulmonary TB is the most prevalent form of disease
in adolescents and adults and the most significant source
of TB transmission, BCG is estimated to have little impact
in limiting TB spread. Several causes have been considered
to explain the variable efficacy of BCG. These includ
differences in BCG strains, host genetic and nutritional
factors, variable virulence among Mycobacterium tubercu-
losis (Mtb), interference of environmental mycobacteria,
switch to a type 2 immunological response in presence of
helminthic infection and variation among trial methods
[3,5,8,12,13]. Recent studies, evaluating interferon-g
(INF-g) release assay (IGRA) results, suggested that BCG
could not only protect against disseminated TB in
children, but also against infection [14].
Several studies demonstrated that a booster dose of
BCG did not improve protection aginst TB [15].
BCG is a safe vaccine in healthy infants. Loco-regional
adverse reaction, including regional adenitis are usually
self-limiting [12]. However, it can cause severe disse-
minated disease, named BCG-osis, in patients affected
by some primary immunodeficiency, such as severe
combined immunodeficiency and chronic granuloma-
tous disease [16]. Different studies revealed an
increased risk of disseminated BCG disease in HIV-
infected children, even if asymptomatic at time of
vaccination [17,18]. Thus, WHO Global Advisory
Committee on Vaccine Safety recommends that BGC
should not be administered in HIV-infected patients
[19]. This is an important limitation, considering that
countries where TB is endemic are the same where
HIV spreads. Since that, a safer and more effective
vaccine is urgently required. In response to this chal-
lenge, the development pipeline now includes 12 vac-
cine candidates [20], that can either boost BCG’s initial
effects (booster vaccine) or replace BCG (priming
vaccine).
The aim of booster vaccines, that include viral vectored
or protein adjuvant vaccines, is to enhance the immune
response of BCG, whereas the priming vaccines aim at
replacing BCG with a safer and long-lasting vaccine, that
can be a recombinant BCG strain or a genetically attenu-
ated Mtb.
A third strategy is to develop therapeutic vaccines
reducing duration of TB therapy.
The aim of this review is to provide updated information
on vaccine entered into clinical trials.
Methods
Data included in this review were retrieved by searches of
Pubmed, references of the relevant articles and open-
access website of Aeras and ClinicalTrial.gov. The search
was limited to English-language studies published between
1st September, 2003 and 1st September 2013. Studies
reporting data on vaccine now in clinical trials were
included in this review. Article were excluded if redundant
or not pertinent on the basis of titles and abstracts.
Articles on pre-clinical studies of vaccine not yet in clinical
trial were excluded.
Search strategy
The search strategy was: Vaccine[Title] AND (tubercu-
losis[Title] OR tb[Title] OR bcg[Title]) AND ("2003/09/
01"[PDAT] : “2013/09/01"[PDAT]) AND (Journal Article
[ptyp] AND English[lang]) NOT ("leishmania"[MeSH
Terms] OR “leishmania"[All Fields]) NOT ("leprosy"[-
MeSH Terms] OR “leprosy"[All Fields]) NOT ("neo-
plasms"[MeSH Terms] OR “neoplasms"[All Fields] OR
“cancer"[All Fields]) NOT ("hypersensitivity"[MeSH
Terms] OR “hypersensitivity"[All Fields] OR “allergy"[All
Fields] OR “allergy and immunology"[MeSH Terms] OR
("allergy"[All Fields] AND “immunology"[All Fields]) OR
“allergy and immunology"[All Fields]) NOT ("vitamin-
s"[Pharmacological Action] OR “vitamins"[MeSH
Terms] OR “vitamins"[All Fields] OR “vitamin"[All
Fields]) NOT ("lactoferrin"[MeSH Terms] OR “lactofer-
rin"[All Fields]).
Results
The search performed generated a total of 461 results. A
total of 100 articles were included in the review (Addi-
tional file 1). Three viral vectored booster vaccines, five
protein adjuvant booster vaccines, two priming vaccines
and two therapeutic vaccines have been analyzed.
Viral-vectored booster vaccines
MVA85A
MVA85A is the most clinically advanced vaccine candi-
date (Table 1). It is the first new TB vaccine to enter
into clinical trials in 2002 and to be tested in infants
since BCG.
It is a recombinant strain of Modified Vaccinia virus
Ankara expressing the Mtb antigen 85A (Ag85A),
designed to enhance response induced by BCG [21].
The live viral vector cannot replicate in human.
Several trials reported its safety in healthy adults, Mtb
and HIV infected patients, adolescents, children and
infants[22-26]. Minor local and systemic reactions are
frequently reported in the first week after immunization.
No serious vaccine-related adverse events have been
reported [22-26].
Vaccine is normally performed intradermally, even if a
phase I trial reported a safe and higher immunogenic
profile of MVA85A delivered intramuscularly in healthy
adults [27].
MVA85A has shown to induce a polyfunctional CD4+
T-cells population, expressing INF-g, interleukin-2 (IL-2),
tumour necrosis factor-a (TNF-a), interleukin-17 (IL-17)
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and granulocyte-macrophage colony-stimulating factor
and a modest CD8+ T-cells response [22,25,26,28,29].
Data showed that a dose of 1 x 108 plaque forming
units was as safe as lower doses and induced a higher
immune response in healthy previously BCG vaccinated
UK adults [23].
However, a recent phase 2b trial on safety and efficacy
of MVA85A was conducted in 2797 healthy South
African infants previously vaccinated with BCG. The
vaccine was well tolerated and immunogenic, but it was
poorly protective against TB infection [22]. Authors
suggested that the immunologic response induced by
the vaccine could not be related to protective effect
against TB infection.
The safety and immunogenicity of MVA85A priming
and BCG-booster vaccination is currently being evaluated
in a phase 2 trial [30].
Moreover, a phase 1 trial testing safety of MVA85A
combined with a different carrier protein, IMX313, is
ongoing [31].
Another poxvirus-vectored candidate vaccine, Fowlpox
virus expressing the Mtb antigen 85A has been entered
clinical trial in 2008 but it failed to induce an adequate
immune-response [32].
AdAg85a
AdAg85a is a recombinant strain of replication-deficient
adenoviral vector expressing the Mtb Ag85A [33] (Table 1).
Experimental data showed that it provided potent
protection against pulmonary TB infection in mice when
administered intranasally, either as priming and as booster
vaccine for BCG [33,34]. Intranasal administration
enhanced a better protection than intramuscular in both
settings [33,34]. In guinea pigs, both intranasal and intra-
muscular vaccination were protective against pulmonary
TB infection. However intranasal route seemed to provide
stronger protection [35].
Santuosso et al. demonstrated that intranasal AdAg85a
was able to elicit robust mucosal CD4+ and CD8+ T-cells
responses in the airway lumen [34,36].
A phase 1 trial evaluating safety and immunogenicity
of AdAg85a administered intramuscularly in previously
and not-previously BCG-vaccinated healthy adults has
been terminated in July 2013 [37].
Mu et al. reported that a new intranasally bivalent
adenovirus-vectored vaccine expressing Ag85A and
TB10.4 antigen provided an improved protection against
TB pulmonary infection in mice [38].
Ad35/Aeras-402
Ad35/Aeras 402 is a recombinant, non-replicating ade-
novirus, serotype 35 vaccine, which expresses a fusion
protein from the Mtb Ag85A, antigens 85B (Ag85B) and
TB10.4 [39] (Table 1).
Good safety profiles have been shown in phase 1 trials
on healthy previously BCG vaccinated adults. No serious
adverse events related to the vaccine have been reported.
However, mild to moderate local adverse events were
frequent [40,41].
Ad35/Areas 402 provided strong CD4+ and CD8+
T-cells responses in mouse, especially if intranasally
administered [39]. Similarly, it was able to induce potent
CD4+ and CD8+ T-cells responses in healthy adults,
with important IFN-g, TNF-a and IL-2 production if
administered as booster BCG vaccine [40,41]. However,
it did not elicit any IL-17 secretion [41].
Trials evaluating safety and immunogenicity of Ad35/
Aeras 402 in infants and HIV-infected adults are ongoing
[42,43]. Moreover, a study to asses safety and immuno-
genicity of Ad35/Aeras 402 followed by MVA85A started
on September 2012 [44].
Protein adjuvant booster vaccines
H1/IC31
H1/IC31 is a recombinant subunit vaccine, composed by
the hybrid protein of Early Secretory Antigenic Target 6
(ESAT6) and Ag85B adjuvanted with IC31, an adjuvant
system composed by the cationic protein polyaminoacid
KLK and oligodeoxynucleotide ODN1a [45] (Table 2).
The fusion protein Ag85B-ESAT6 has been extensively
evaluated in several animal models and combined with
different adjuvants [46-49].
H1/IC31 has been shown to be safe in healthy adults.
No serious adverse events related to the vaccine have
been reported. Local and systemic described events were
mild and quickly resolving (<48 hours) [45,50,51].
H1/IC31 provided long-lasting TH1 responses either in
mycobacterially-naïve subjects as well in BCG-vaccinated
or previously TB infected voluntaries. The immune
response can be amplified by booster vaccinations. H1/
IC31 induce a weak immune response against ESAT6;
however this vaccine provided a more potent protective
effect than a vaccine with Ag85B alone [45,50,51].
IGRAs measure the amount of INF-g produced by
lymphocytes after in vitro incubation with Mtb antigens,
included ESAT6. Even if H1/IC31 has shown to induce
Table 1 Viral vectored booster vaccines
Vaccine Name Composition Primary type Development phase
MVA85A Modified Vaccinia virus Ankara expressing Ag85A Booster vaccine Phase 2b
Ad5Ag85A Recombinant adenovirus 5 expressing Ag85A Booster vaccine Phase 1
Ad35 Recombinant adenovirus 35 expressing Ag85A-Ag85B-TB10.4 fusion protein Booster vaccine Phase 1/2
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QuantiFERON positivity in only few subjects, further
studies evaluating possible interference of the vaccine
with IGRA results are needed [45,50,51].
HyVac4/Aeras 404
HyVac4/Aeras 404 is a booster vaccine developed by the
same group of H1/IC31. The antigen ESAT6 was replaced
by TB10.4, to avoid the interference with IGRAs and the
fusion protein was combined with the adjuvant IC31 [52]
(Table 2).
Dietrich et al. demonstrated that the fusion protein
Ag85B-TB10.4 (HyVac4) combined with the adjuvant pro-
tein dimethyl dioctadecyl ammonium/monophosphoryl
lipid A (DDA/MPL) was highly immunogenic and induced
strong protection against TB in mice model [53].
HyVac 4/Aeras 404 is safe and protective against pul-
monary TB when administered as priming or booster
vaccine in guinea pigs and mice [52,54]. When used as
booster vaccine for BCG in mouse model, it induced
expression of IFN-g, TNF-a and IL-2 triple positive
CD4+ T-cells that seemed to be correlated with protection
against TB [54].
Several phase I trials on HyVac4/Aeras 404 have been
terminated [55] and a phase I/II trial on its safety and
immunogenicity in BCG vaccinated healthy infants is
ongoing [56].
ID93/GLA-SE
ID93/GLA-SE is a protein-adjuvant vaccine, composed by
ID93, a fusion protein comprising four Mtb antigens
(Rv2608, Rv3619, Rv3620 and Rv1813), combined with the
glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE)
[57] (Table 2).
ID93/GLA-SE induced a significant TH1 immune
response, with multifunctional IFN-g, TNF-a and IL-2
CD4+ T-cells production in BCG-vaccinated or not-
vaccinated mice and guinea pigs [57,58]. That response
led a strong protection against pulmonary TB. More-
over, it was well tolerated and induced TH1 and TH2
CD4+T-cells responses in BCG-vaccinated non-humans
primates and it elicited CD4+ and CD8+ T-cells
responses in BCG-vaccinated or TB-exposed human
peripheral blood mononuclear cells [57]. In contrast, if
combined with SE alone, ID93 elicited a Th2 immune
response, that did not improve protection against
pulmonary TB in mouse and guinea pig models [58].
Experimental data showed that ID93/GLA-SE protected
also against MDR-TB in animal models [57].
Baldwin et al. demonstrated that ID93 combined with
an adenovirus type 5 vector induced strong CD8+ T-cells
responses, but it did not provide long-lived immune
responses if not combined with a priming or booster
ID93/GLA-SE vaccination [59]
Two clinical trials evaluating safety, tolerability and
immunogenicity of ID93/GLA-SE in healthy adults,
either as priming vaccine as well as booster vaccine, are
ongoing [60,61].
H56/IC31
H56/IC31 is a protein-adjuvant vaccine composed by
H56, a fusion protein containing Ag85B, ESAT6 and the
latency-associated protein Rv2660c, combined with the
adjuvant IC31 [62] (Table 2). In mouse models, H56 eli-
cited a strong multifunctional CD4+T-cells response and
limited reactivation of latent TB [63].
Lin et al. demonstrated that H56/IC31 was safe and
immunogenic in BCG-vaccinated non-human primate
models. Moreover the vaccine showed excellent control
of latent infection [62]. Notably, in vaccinated non-
human primate anti-TNF antibodies treatment did not
induce reactivation of latent TB [62].
A phase 1/2a trial on safety and immunogenicity of
H56/IC31 in HIV-negative, BCG vaccinated with or
without latent TB is ongoing [64].
M72/AS01E
M72/AS01E is a recombinant vaccine developed to
boost BCG-induced or Mtb-induced immune response
(Table 2).
The M72 antigen is strictly related to Mtb72F, a fusion
protein comprising the Mtb39a and Mtb32a antigens [65].
A point mutation was performed in the Mtb32a antigen of
M72 to improve the long-term stability of Mtb72F [66].
AS01E is an adjuvant system containing the immunosti-
mulants MPL and Quillaja saponaria fraction 1 (QS21)
combined with liposomes [66]. It induced humoral and
TH1 cellular responses [65].
Mtb72F, combined with the adjuvant AS02 (oil-in-water
emulsion of MPL and QS21) has been tested in mice, gui-
nea pigs, rabbits and non-human primates models,
revealed good safety and immunogenicity profiles [67-69].
Moreover, Mtb72F/AS02 was rather well tolerated and
Table 2 Protein adjuvant booster vaccines
Vaccine Name Composition Primary type Development phase
H1/IC31 ESAT6-Ag85B fusion protein + IC31 adjuvant Booster vaccine Phase 1
HyVac4 TB10.4-Ag85B fusion protein + IC31 adjuvant Booster vaccine Phase 1/2
ID93/GLA-SE Rv2608-Rv3619-Rv3620-Rv1813 fusion protein + GLA-SE adjuvant Booster vaccine Phase 1
H56/IC31 Ag85B-ESAT6-Rv2660c fusion protein + IC31 adjuvant Booster vaccine Phase1/2a
M72/AS01E Mtb39a-Mtb32a fusion protein + AS01E adjuvant Booster vaccine Phase 2
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immunogenic in adults with or without previous exposure
to Mtb or BCG [65,70].
Meanwhile, concerns for the real effectiveness of
Mtb72f have emerged do to variation in Mtb32a and
Mtb39a antigens sequences in different Mtb strains [71].
M72/AS01E presented frequent local adverse events,
resolving within one week of vaccination, predominantly
due to the adjuvant. No serious adverse events related
to the vaccination have been reported [66,72].
M72/AS01E induced long-lasting multifunctional
CD4+T-cells responses in adults with or without BCG
or Mtb contacts, that was higher than the responses
elicited by the AS02-adjuvanted vaccine. As shown in
MVA85A, M72/AS01E seemed not to induce robust
CD8+T-cells responses [66,72].
Phase 2 trials on safety and immunogenicity of M72/




VPM1002 is a recombinant BCG strain that expresses
membrane-perforating listeriolysin (encoded by the gene
hly) of Listeria monocytogenes, lacking the urease C
gene (BCG ΔureC::hly) and that contains a hygromycin
resistance marker [75] (Table 3).
It has shown to produce a better protection against
TB by stimulating type 1 and type 17 cytokines in mice
compared with parental BCG (pBCG) [76]. Moreover, in
a mouse model, apoptotic vescicles from BCG ΔureC::
hly-infected macrophages induced greater CD4+ and
CD8+ T-cells responses than pBCG [77].
VPM1002 was safe in healthy adults, with adverse
events profile comparable to BCG. No serious adverse
events related to the vaccine have been reported and no
human-to-human transmission has been documented
[75]. VPM1002 induced robust CD4+ and CD8+ T-cells
and antibodies responses [75].
A phase 2 trial evaluating safety and immunogenicity
of VPM1002 in comparison with BCG in newborns is
ongoing [78].
Notably, the recombinant BCG strain Aeras 422, that
showed promising results in animal models , failed to
overcome phase 1 trial, do to some reactivation of shingles
in vaccinated healthy adults [79] and the development of
rBCG30 strain, an overexpressing Ag85B recombinant
vaccine that showed safety and immunogenicity in a phase
1 trial, did not carry on [80].
MTBVAC
MTBVAC is the first live-attenuated Mtb vaccine
entered in phase 1 clinical trial in January 2013 [81]
(Table 3).
It derives from the SO2, an attenuated strain obtained
by the insertion of a kanamycin-resistance cassette in
the phoP gene of Mtb. phoP is a transcription regulator,
therefore its mutation determines lack of expression of
several genes, including virulence factors, such as
ESAT6 [82]. Although SO2 seemed to be immunogenic
and protective against TB in animal models [82,83], it
failed to satisfy the Geneva consensus requirements for
progressing new vaccines into clinical trials [81].
Hence, the same research group developed a new vac-
cine strain, with tow stable mutations in the phoP and
fadD26 genes [81]. fadD26 product is required for the
synthesis of phthiocerol dimycocerosates, a component of
cell envelope that protect Mtb from host defenses [84].
MTBVAC was safe, immunogenic and protective
against TB in mouse and guinea pig models [81]. Since
it was functionally comparable to SO2, it has been
authorized to enter in clinical trial after these tests.
Therapeutic vaccines
RUTI®
RUTI® is a therapeutic vaccine constituted by detoxified
liposomal fragments of Mtb [85] (Table 4). It was devel-
oped to complete latent TB treatment after a short
course of antimicrobial therapy [85,86]. Experimental
data showed that RUTI® is safe and able to elicit TH1-
TH2-TH3 responses in animal models. Moreover, CD8
+
T-cells and antibodies responses have been reported
[85,87].
A phase 1 trial revealed that RUTI® administered sub-
cutaneously was rather well tolerated in BCG-naïve
healthy adults, except local reaction. No serious adverse
events have been reported [88]. Moreover, it induced a
specific cellular and humoral responses [88].
Mycobacterium vaccae
A whole inactivated Mycobacterium vaccae (MV)
administered intradermally was firstly evaluated as a
therapeutic vaccine (Table 4). Clinical trials showed con-
flicting results [89]. A meta-analysis on MV added TB
chemotherapy in never-treated TB patients, showed that
it is effective in improving both sputum conversion and
X-ray imagines [90].
More recently, MV was tested as prophylactic vaccine
to prevent TB, especially in HIV-infected patients
Table 3 Priming vaccines
Vaccine Name Composition Primary type Development phase
VPM1002 Recombinant BCG strain Priming vaccine Phase 2
MTBVAC Live-attenuated Mycobacterium tuberculosis Priming vaccine Phase 1
Montagnani et al. BMC Infectious Diseases 2014, 14(Suppl 1):S2
http://www.biomedcentral.com/1471-2334/14/S1/S2
Page 5 of 9
[91-93]. MV was well tolerated and no serious adverse
events have been reported. A meta-analysis revealed that
MV was able to prevent TB in high risk category and
was safe and immunogenic in HIV-infected patients [94].
In a phase 3 trial, MV has shown to induce variable
IFN-g and humoral responses, according to CD4+ T-cells
count, HIV viral load and previous TB treatment [95].
Conclusions
One of the WHO’s MDG is to reduce TB incidence by
2015 and one of the Stop TB Partnership targets is to era-
dicate TB by 2050. Hence, combined strategies based on
faster diagnostic tools, drugs effective against MDR TB
and able to shortness duration of treatment and vaccines
are essential to reach these targets.
Several vaccines against TB are in the pipeline, either
as priming, booster and therapeutic vaccines. Since the
three options operate at different levels (pre-exposure or
post-exposure), they can be considered complementary
and hopefully they can succeed in eradicating TB.
Notably, as seen for MVA85A, vaccines that resulted
to be immunogenic in animal models and humans can
failed to show effectiveness in late phase trials [22].
Therefore, immune mechanisms of protection against
TB should be simultaneously explored.
The existence of several lines of research can mean
that a main road does not exist at the present.
Finally, even if several vaccines are in the pipeline,
further investments on basic research, clinical testing
and mass vaccination campaigns are essential to achieve
the ambitious goals of eradication.
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